Dysmenorrhea – Pipeline Insight, 2020
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Dysmenorrhea – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dysmenorrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Dysmenorrhea: Overview
Dysmenorrhea causes severe and frequent cramps and pain during your period. It may be either primary or secondary.
The following are the most common symptoms of dysmenorrhea. However, each person may experience symptoms differently. Symptoms may include:
To diagnose dysmenorrhea, the health care provider will evaluate your medical history and do a complete physical and pelvic exam. Other tests may include:
Treatment to manage dysmenorrhea symptoms may include:
This segment of the Dysmenorrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dysmenorrhea Emerging Drugs
Further product details are provided in the report……..
Dysmenorrhea: Therapeutic Assessment
This segment of the report provides insights about the different Dysmenorrhea drugs segregated based on following parameters that define the scope of the report, such as:
Dysmenorrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dysmenorrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dysmenorrhea drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Dysmenorrhea – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dysmenorrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Dysmenorrhea: Overview
Dysmenorrhea causes severe and frequent cramps and pain during your period. It may be either primary or secondary.
- Primary dysmenorrhea. This occurs when you first start your period and continues throughout your life. It is usually life-long. It can cause severe and frequent menstrual cramping from severe and abnormal uterine contractions.
- Secondary dysmenorrhea. This type is due to some physical cause. It usually starts later in life. It may be caused by another medical condition, such as pelvic inflammatory disease or endometriosis.
The following are the most common symptoms of dysmenorrhea. However, each person may experience symptoms differently. Symptoms may include:
- Cramping in the lower abdomen
- Pain in the lower abdomen
- Low back pain
- Pain radiating down the legs
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Weakness
- Fainting
- Headaches
To diagnose dysmenorrhea, the health care provider will evaluate your medical history and do a complete physical and pelvic exam. Other tests may include:
- Ultrasound. This test uses high-frequency sound waves to create an image of the internal organs.
- Magnetic resonance imaging (MRI). This test uses large magnets, radiofrequencies, and a computer to make detailed images of organs and structures within the body.
- Laparoscopy. This minor procedure uses a laparoscope. This is a thin tube with a lens and a light. It is inserted into an incision in the abdominal wall. Using the laparoscope to see into the pelvic and abdomen area, the doctor can often detect abnormal growths.
- Hysteroscopy. This is the visual exam of the canal of the cervix and the inside of the uterus. It uses a viewing instrument (hysteroscope) inserted through the vagina.
Treatment to manage dysmenorrhea symptoms may include:
- Prostaglandin inhibitors, such as nonsteroidal anti-inflammatory medications, or NSAIDs, such as aspirin and ibuprofen (to reduce pain)
- Acetaminophen
- Oral contraceptives (ovulation inhibitors)
- Progesterone (hormone treatment)
- Diet changes (to increase protein and decrease sugar and caffeine intake)
- Vitamin supplements
- Regular exercise
- Heating pad across the abdomen
This segment of the Dysmenorrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dysmenorrhea Emerging Drugs
- Pelubiprofen - Daewon Pharmaceutical
- Pure Femme Tablets: Pure Green
- PNB 001: PNB Vesper Life Science
Further product details are provided in the report……..
Dysmenorrhea: Therapeutic Assessment
This segment of the report provides insights about the different Dysmenorrhea drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Dysmenorrhea
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Dysmenorrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dysmenorrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dysmenorrhea drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dysmenorrhea R&D. The therapies under development are focused on novel approaches to treat/improve Dysmenorrhea.
- Intellectual property of PNB-001 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World. USPTO has issued the patent on December 28, 2014.
- Dysmenorrhea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dysmenorrhea drugs?
- How many Dysmenorrhea drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dysmenorrhea?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dysmenorrhea therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dysmenorrhea and their status?
- What are the key designations that have been granted to the emerging drugs?
- Daewon Pharmaceutical
- Pure Green
- PNB Vesper Life Science Nobelpharma
- Bayer
- Laboratorios Andromaco
- Juniper Pharmaceuticals
- Vantia
- PDC Biotech GmbH
- NPC-16
- BAY86-5300
- Meloxicam
- Lidocaine
- VA111913
- PDC31
- Pelubiprofen
- Pure Femme Tablets
- PNB 001
Introduction
Executive Summary
Dysmenorrhea: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dysmenorrhea – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Dysmenorrhea companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dysmenorrhea Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pelubiprofen - Daewon Pharmaceutical
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Pure Femme Tablets: Pure Green
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PNB 001: PNB Vesper Life Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Dysmenorrhea Key Companies
Dysmenorrhea Key Products
Dysmenorrhea- Unmet Needs
Dysmenorrhea- Market Drivers and Barriers
Dysmenorrhea- Future Perspectives and Conclusion
Dysmenorrhea Analyst Views
Dysmenorrhea Key Companies
Appendix
Executive Summary
Dysmenorrhea: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dysmenorrhea – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Dysmenorrhea companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dysmenorrhea Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pelubiprofen - Daewon Pharmaceutical
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Pure Femme Tablets: Pure Green
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PNB 001: PNB Vesper Life Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Dysmenorrhea Key Companies
Dysmenorrhea Key Products
Dysmenorrhea- Unmet Needs
Dysmenorrhea- Market Drivers and Barriers
Dysmenorrhea- Future Perspectives and Conclusion
Dysmenorrhea Analyst Views
Dysmenorrhea Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Dysmenorrhea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Dysmenorrhea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Dysmenorrhea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Dysmenorrhea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
